---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-106631"
form_type: "8-K"
ticker: "TECH"
cik: "0000842023"
company_name: "BIO-TECHNE Corp"
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:28:57.541372+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bio-Techne Q1 FY2026 revenue down 1% to $286.6M; adjusted EPS flat $0.42; declares $0.08 dividend

## Summary
- Revenue $286.6M (-1% YoY); GAAP EPS $0.24 (up from $0.21); adjusted EPS $0.42 (flat).
- Protein Sciences segment rev $202.2M (-1% YoY); op margin 38.4% vs 39.4%.
- Diagnostics & Spatial Biology rev $79.5M (-4%), organic +3%; op margin 11.2% vs 5.1% (benefited from Exosome divestiture).
- Completed Exosome Diagnostics divestiture; CEO notes biotech funding headwinds but stability in US academic.
- Declares quarterly dividend $0.08/share, payable Nov 28 to holders of record Nov 17.

## SEC filing metadata
- accession: 0001104659-25-106631
- form_type: 8-K
- ticker: TECH
- cik: 0000842023
- company_name: BIO-TECHNE Corp
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/842023/000110465925106631/0001104659-25-106631-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/842023/000110465925106631/tech-20251030x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-106631
- JSON: https://secwatch.observer/filing/0001104659-25-106631.json
- Plain text: https://secwatch.observer/filing/0001104659-25-106631.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.